NCT06746883View on ClinicalTrials.gov

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
OTHER

Non-interventional

Non-interventional

Trial Locations (4)

29605

NOT_YET_RECRUITING

Prisma Health - Infectious Diseases - Greenville, Greenville

70121-2429

NOT_YET_RECRUITING

Ochsner Medical Center - New Orleans, New Orleans

71103-4228

RECRUITING

Ochsner LSU Health Science Center Shreveport, Shreveport

44304-1430

RECRUITING

Summa Health System - Akron - 75 Arch Street, Akron

Sponsors
All Listed Sponsors
lead

Innoviva Specialty Therapeutics

INDUSTRY

NCT06746883 - A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection | Biotech Hunter | Biotech Hunter